{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:36:23Z","timestamp":1787567783922,"version":"build-2736575974"},"reference-count":30,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background: Patient-specific targeted radionuclide therapy (TRT) requires consideration not only of administered activity but also of the spatial distribution of radiopharmaceutical uptake and radionuclide-specific energy deposition. This study developed a voxel-based computational workplan to compare 177Lu, 161Tb and 90Y, together with hybrid radionuclide models, using patient-specific PSMA PET-derived tumour activity distributions. Methods: PSMA PET\/CT data from 20 patients with prostate cancer, comprising 10 18F-PSMA and 10 68Ga-PSMA examinations, were processed to obtain 2285 quality-filtered lesions. Radionuclide-specific dose-point kernels (DPKs) were generated in water using OpenGATE and applied to voxel-wise lesion activity distributions to reconstruct absorbed-dose maps. Kernel characteristics were evaluated using radial energy-containment metrics, and 177Lu, representing 161Tb simulations, was subjected to grid-convergence testing and external comparison with a published DPK. Lesion dosimetry was assessed using Dmean, D90, D95, equivalent uniform dose (EUD) and tumour control probability (TCP), with uncertainty quantified using patient-cluster bootstrap confidence intervals. Kinetic sensitivity and diagnostic tracer subgroup analyses were additionally performed. Results: The study showed that 161Tb produced the highest median lesion-level Dmean, D90, D95 and EUD at 182.79, 136.28, 132.07 and 148.53 Gy, respectively, with a median TCP of 0.981. Corresponding values for 177Lu were 141.33, 105.42, 102.10 and 114.78 Gy (TCP 0.930), while 90Y produced lower local dose metrics but the broadest radial dose distribution, consistent with its longer-range \u03b2-particle crossfire. 161Tb remained the highest-ranking radionuclide across the investigated kinetic cases and within both diagnostic tracer subgroups. Hybrid 161Tb\/90Y kernels provided a controllable compromise between localised energy deposition and extended crossfire; a 70:30 model increased central dose localisation while retaining an R90 and R95 of 6 and 7 mm, respectively. Grid-convergence and published-DPK comparisons supported the numerical adequacy of the kernel methodology. Radionuclide emission characteristics substantially influence the transformation of heterogeneous tumour uptake into spatial absorbed-dose distributions. Within this model, 161Tb provided the strongest overall lesion-level dosimetric performance, whereas the extended range of 90Y may offer complementary crossfire for selected bulky or heterogeneous lesions. Conclusions: The findings support phenotype-informed radionuclide comparison and provide a computational basis for investigating hybrid strategies. However, the absolute dose estimates and proposed radionuclide combinations remain model-based and require validation using serial therapeutic imaging, heterogeneous patient-specific dosimetry and normal-organ dose constraints before clinical translation.<\/jats:p>","DOI":"10.3390\/diseases14090305","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:20:02Z","timestamp":1787563202000},"page":"305","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Dosimetry of Single and Hybrid 177Lu, 161Tb, and 90Y in PSMA-Targeted Therapy"],"prefix":"10.3390","volume":"14","author":[{"given":"Olatunde Michael","family":"Oni","sequence":"first","affiliation":[{"name":"Nuclear Futures Institute, School of Computer Sciences and Engineering, Bangor University, Dean Street, Bangor LL57 1UT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3945-630X","authenticated-orcid":false,"given":"Tim A. D.","family":"Smith","sequence":"additional","affiliation":[{"name":"Nuclear Futures Institute, School of Computer Sciences and Engineering, Bangor University, Dean Street, Bangor LL57 1UT, UK"},{"name":"Division of Cancer Sciences, University of Manchester, Manchester M20 4GJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2967\/jnumed.121.262305","article-title":"Dosimetry in radiopharmaceutical therapy","volume":"63","author":"Zanzonico","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.21037\/qims-20-1006","article-title":"Recent advances in voxel-based targeted radionuclide therapy dosimetry","volume":"11","author":"Mok","year":"2021","journal-title":"Quant. Imaging Med. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/mp.16729","article-title":"Technical note: Impact of dose voxel kernel (DVK) values on dosimetry estimates in 177Lu and 90Y radiopharmaceutical therapy applications","volume":"51","author":"Danieli","year":"2024","journal-title":"Med. Phys."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1002\/mp.13789","article-title":"Dose point kernels for 2174 radionuclides","volume":"46","author":"Graves","year":"2019","journal-title":"Med. Phys."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s13139-022-00769-z","article-title":"Voxel-Based Internal Dosimetry for 177Lu-Labeled Radiopharmaceutical Therapy Using Deep Residual Learning","volume":"57","author":"Kim","year":"2023","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ramonaheng, K., Qebetu, M., Ndlovu, H., Swanepoel, C., Smith, L., Mdanda, S., Mdlophane, A., and Sathekge, M. (2024). Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium. Front Nucl. Med., 4.","DOI":"10.3389\/fnume.2024.1355912"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Huang, M., Law, H.K.W., and Tam, S.Y. (2025). Radiomics-Driven Tumor Prognosis Prediction Across Imaging Modalities: Advances in Sampling, Feature Selection, and Multi-Omics Integration. Cancers, 17.","DOI":"10.3390\/cancers17193121"},{"key":"ref_8","first-page":"11S","article-title":"MIRD pamphlet No. 17: The dosimetry of nonuniform activity distributions\u2014Radionuclide S values at the voxel level","volume":"40","author":"Bolch","year":"1999","journal-title":"J. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1088\/0031-9155\/57\/2\/517","article-title":"A free database of radionuclide voxel S values for the dosimetry of nonuniform activity distributions","volume":"57","author":"Lanconelli","year":"2012","journal-title":"Phys. Med. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e230024","DOI":"10.1148\/ryai.230024","article-title":"TotalSegmentator: Robust Segmentation of 104 Anatomic Structures in CT Images","volume":"5","author":"Wasserthal","year":"2023","journal-title":"Radiol. Artif. Intell."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0146-664X(75)80008-6","article-title":"Texture analysis using grey level run lengths","volume":"4","author":"Galloway","year":"1975","journal-title":"Comput. Graph. Image Process."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1357002","DOI":"10.1142\/S0218001413570024","article-title":"Shape and texture indexes application to cell nuclei classification","volume":"27","author":"Thibault","year":"2013","journal-title":"Int. J. Pattern Recognit. Artif. Intell."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10888-011-9188-x","article-title":"The origins of the Gini index: Extracts from Variabilit\u00e0 e Mutabilit\u00e0 (1912) by Corrado Gini","volume":"10","author":"Ceriani","year":"2012","journal-title":"J. Econ. Inequal."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14516","DOI":"10.1038\/s41598-020-70758-9","article-title":"Objective homogeneity quantification of a periodic surface using the Gini coefficient","volume":"10","author":"Lechthaler","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1118\/1.4737096","article-title":"A dose point kernel database using GATE Monte Carlo simulation toolkit for nuclear medicine applications: Comparison with other Monte Carlo codes","volume":"39","author":"Papadimitroulas","year":"2012","journal-title":"Med. Phys."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Walrand, S., and Jamar, F. (2021). Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead. Int. J. Mol. Sci., 22.","DOI":"10.20944\/preprints202105.0445.v1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"935351","DOI":"10.1155\/2013\/935351","article-title":"Kidney dosimetry in 177Lu and 90Y peptide receptor radionuclide therapy: Influence of image timing, time-activity integration method, and risk factors","volume":"2013","author":"Guerriero","year":"2013","journal-title":"BioMed Res. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"113777","DOI":"10.1016\/j.radphyschem.2026.113777","article-title":"Simulation-based dosimetric and radiobiological modeling of advanced radiotherapy delivery platforms for prostate cancer","volume":"244","year":"2026","journal-title":"Radiat. Phys. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.nucmedbio.2011.02.007","article-title":"The low-energy \u03b2\u2212 and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy","volume":"38","author":"Lehenberger","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40658-020-00301-2","article-title":"Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases","volume":"7","author":"Ferreira","year":"2020","journal-title":"EJNMMI Phys."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13550-016-0171-1","article-title":"Contribution of Auger\/conversion electrons to renal side effects after radionuclide therapy: Preclinical comparison of 161Tb-folate and 177Lu-folate","volume":"6","author":"Haller","year":"2016","journal-title":"EJNMMI Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40658-025-00810-y","article-title":"Monte Carlo-based subcellular comparison of electron energy deposition by 177Lu and 161Tb: Implications for targeted radiopharmaceutical therapy","volume":"12","author":"Velo","year":"2025","journal-title":"EJNMMI Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1118\/1.3608909","article-title":"Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies","volume":"38","author":"Dezarn","year":"2011","journal-title":"Med. Phys."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2967\/jnumed.115.159012","article-title":"MIRD Pamphlet No. 26: Joint EANM\/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy","volume":"57","author":"Ljungberg","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.2967\/jnumed.110.077149","article-title":"Fine-resolution voxel S values for constructing absorbed dose distributions at variable voxel size","volume":"51","author":"Hobbs","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s13246-014-0277-6","article-title":"Effect of voxel size when calculating patient specific radionuclide dosimetry estimates using direct Monte Carlo simulation","volume":"37","author":"Hickson","year":"2014","journal-title":"Australas. Phys. Eng. Sci. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.2967\/jnumed.124.267650","article-title":"Clinical Trial Protocol for VIOLET: A Single-Center, Phase I\/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T","volume":"65","author":"Buteau","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","article-title":"First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase \u00bd study","volume":"26","author":"Buteau","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"112132","DOI":"10.1016\/j.apradiso.2025.112132","article-title":"PENELOPE Dose assessment comparison for 177Lu and 161Tb using paediatric computational phantoms","volume":"226","author":"Valente","year":"2025","journal-title":"Appl. Radiat. Isot."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/9\/305\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:41:55Z","timestamp":1787564515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/9\/305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["diseases14090305"],"URL":"https:\/\/doi.org\/10.3390\/diseases14090305","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}